Groupe d'Etude en Oncologie du Quebec

Affichage 21 à 22 des 22 essais cliniques
1 | 2 | 3 |

ESSAIS CLINIQUES No essai ClinicalTrials.gov ID		Phase	Coordonnateur(rice)
(EN) A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide MonumenTAL-6 NCT06208150 Actif en recrutement	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX		Marie-Pier Lecours-Cyr 514-252-3400 poste 5037
(EN) A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide MajesTEC-9 NCT05572515 Actif en recrutement	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX		Marie-Pier Lecours-Cyr 514-252-3400 poste 5037

1 | 2 | 3 |

Groupe d'étude en oncologie du Québec